Fish oil supplementation is associated with cardiovascular benefits in patients with stage 5 chronic kidney disease following creation of a synthetic arteriovenous graft for hemodialysis access, according to study findings published in the Journal of the American Medical Association (2012;307:1809-1816).
In the study, 99 patients took four 1 gram capsules of fish oil and 97 took placebo on the seventh day following graft creation. After 12 months, compared with the placebo group, the fish-oil group experienced a lower rate of graft failure (3.43 vs. 5.95 per 1,000 access-days), half as many thromboses (1.71 vs. 3.41 per 1,000 access-days), fewer corrective interventions (2.89 vs. 4.92 per 1,000 access-days), improved cardiovascular-event-free survival, and lower mean systolic blood pressure. Loss of native patency did not differ significantly between the groups, however.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.